Iterative optimal design of PET experiments for estimating β-adrenergic receptor concentration

Medical and Biological Engineering and Computing

Volumn 38, Issue 6, 2000, Pages 593-602

  Muzic Jr , R F ^a,b   Saidel, G M ^a   Zhu, N ^a   Nelson, A D ^a,b   Zheng, L ^b   Berridge, M S ^b  

^a Case Western Reserve University   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Optimal design; PET; Receptor concentration

Indexed keywords

FLUORINE COMPOUNDS; ITERATIVE METHODS;

BETA ADRENERGIC RECEPTOR CONCENTRATION; FLUOROCARAZOLOL; LIGAND;

POSITRON EMISSION TOMOGRAPHY;

BETA ADRENERGIC RECEPTOR; CARAZOLOL; FLUORINE 18; FLUOROCARAZOLOL F 18; LIGAND; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL PROTOCOL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE; DRUG TISSUE LEVEL; ENANTIOMER; EXPERIMENTATION; FEMALE; HEART MUSCLE; IN VITRO STUDY; IN VIVO STUDY; INJECTION; ISOTOPE LABELING; MALE; METHODOLOGY; MODEL; MUSCLE LEVEL; NONHUMAN; PARAMETER; POSITRON EMISSION TOMOGRAPHY; SIMULATION; SWINE;

EID: 0034318949     PISSN: 01400118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02344863     Document Type: Article

References (32)

1. 'Autoradiographic demonstration of increased scrotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims'
2. 'Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases'
3. 'Beta 1- and beta 2-adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure
4. 'Chemical signaling in the brain'
5. 'Experimental design optimisation: Theory and application to estimation of receptor model parameters using dynamic positron emission tomography'
6. 'Identifiability analysis and parameter identification of an in vivo ligand-receptor model from PET data'
7. 'Non-invasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart
8. 'Cardiac beta-adrenergic receptor density measured in vivo using PET, CGP 12177, and a new graphical method (published erratum appears in J. Nucl. Med., 1994, 35, 921)'
9. 'Quantification of myocardial muscarinic receptors with PET in humans'
10. '(S,S)- and (S,R)-1 '- [18F]fluorocarazolol, ligands for the visualization of pulmonary beta-adrenergic receptors with PET'
11. 'Astrocytes cultured from specific brain regions differ in their expression of adrenergic binding sites'
12. 'Refeeding hypertension in dietary obesity'
13. 'A new fast algorithm for the evaluation of regions of interest and statistical uncertainty in computed tomography'
14. 'Age-related decrease of 11C-N-methylspiperone in vivo binding to human striatum detected by PET'
15. 'A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography'
16. 'Optimal design of experiments to estimate LDL transport parameters in arterial wall'
17. 'Comparison of two compartmental models for describing receptor ligand kinetics and receptor availability in multiple injection PET studies'
18. 'Method to account for scatter, spillover and partial volume effects in region of interest analysis in PET'
19. 15O autoradiographic CBF model in PET'
20. 'Optimal experiment design for PET quantification of receptor concentration'
21. 'Continuous arterial positron monitor for quantitation in PET imaging'
22. 'Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains'
23. 'Brain nicotine receptor deficits in Alzheimer patients as studied by positron emission tomography technique'
24. 3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains'
25. 'Regulation of beta-adrenergic receptors: Impaired desensitization in myocardial ischemia'
26. 'Canine myocardial beta-adrenergic, muscarinic receptor densities after denervation: A PET study (see comments)'
27. 18F]fluorocarazolol in plasma of humans, rats and sheep'
28. 'Performance evaluation of the positron scanner ECAT EXACT'
29. 18F labeling of fluorocarazolol, a high-affinity beta-adrenergic receptor antagonist'